Latest

2 stories

Hide weekly roundups

Wednesday, August 5

Quarterly updatefurosemide injection 80 mg/ 10 ml insulin human Mannkind Corporation

MannKind reports Q2 2026 results with pediatric Afrezza and Furoscix ReadyFlow approvals

MannKind said it hit three 2026 catalysts in the quarter, including FDA approvals for pediatric Afrezza and the Furoscix ReadyFlow autoinjector, plus positive nintedanib DPI Phase 1b data.

SEC filing

Friday, July 24

Financingfurosemide injection 80 mg/ 10 ml Mannkind Corporation

MannKind raises $50 million in private placement tied to Furoscix ReadyFlow approval

MannKind entered the securities purchase agreement on July 23, 2026 and closed the financing the next day, using proceeds partly to fund a $45 million milestone payment triggered by an FDA approval.

SEC filing